Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis.

O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR.

Angiology. 2013 Nov;64(8):576-82. doi: 10.1177/0003319712467223. Epub 2012 Nov 27. Review.

PMID:
23188834
2.

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.

Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.

Am Heart J. 2003 Dec;146(6):E23.

PMID:
14661012
3.

The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.

Wu MY, Hsiang HF, Wong CS, Yao MS, Li YW, Hsiang CY, Bai CH, Hsu YH, Lin YF, Tam KW.

Int Urol Nephrol. 2013 Oct;45(5):1309-18. doi: 10.1007/s11255-012-0363-1. Epub 2013 Jan 3. Review.

PMID:
23283594
4.

Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

Bagshaw SM, Ghali WA.

Arch Intern Med. 2005 May 23;165(10):1087-93. Review.

PMID:
15911721
5.

N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.

Zagler A, Azadpour M, Mercado C, Hennekens CH.

Am Heart J. 2006 Jan;151(1):140-5.

PMID:
16368307
6.

Preventive effect of N-acetylcysteine on contrast-induced nephropathy following coronary angiography and angioplasty.

Kamiyama N, Ogawa R, Hamada H, Ohno T, Asano R, Umemura J, Yoshida H.

Yakugaku Zasshi. 2008 Sep;128(9):1333-9.

8.

Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.

Bilasy ME, Oraby MA, Ismail HM, Maklady FA.

J Interv Cardiol. 2012 Aug;25(4):404-10. doi: 10.1111/j.1540-8183.2012.00730.x. Epub 2012 May 22.

PMID:
22612071
9.

Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.

Chousterman BG, Bouadma L, Moutereau S, Loric S, Alvarez-Gonzalez A, Mekontso-Dessap A, Laissy JP, Rahmouni A, Katsahian S, Brochard L, Schortgen F.

J Crit Care. 2013 Oct;28(5):701-9. doi: 10.1016/j.jcrc.2013.03.007. Epub 2013 May 15.

PMID:
23683568
10.

N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.

Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS.

Am Heart J. 2009 Mar;157(3):576-83. doi: 10.1016/j.ahj.2008.11.010. Epub 2009 Feb 6.

PMID:
19249432
11.

Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.

Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O.

Int J Cardiol. 2012 Mar 22;155(3):418-23. doi: 10.1016/j.ijcard.2010.10.041. Epub 2010 Nov 23.

PMID:
21106264
12.

Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.

Alessandri N, Lanzi L, Garante CM, Tersigni F, Sergiacomi R, Petrassi M, Di Matteo A, Tufano F.

Eur Rev Med Pharmacol Sci. 2013 Feb;17 Suppl 1:13-21.

13.

Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.

Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H, Lee MH.

Int J Cardiol. 2010 Feb 4;138(3):239-45. doi: 10.1016/j.ijcard.2008.08.013. Epub 2008 Sep 14.

PMID:
18793808
14.

N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.

Kang X, Hu DY, Li CB, Ai ZS, Peng A.

Ren Fail. 2015 Nov;37(10):297-303. doi: 10.3109/0886022X.2015.1012985. Epub 2015 Oct 13. Review.

PMID:
26458505
15.

The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy.

Guru V, Fremes SE.

Clin Nephrol. 2004 Aug;62(2):77-83. Review.

PMID:
15356963
16.

Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.

Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z.

PLoS One. 2013;8(1):e55124. doi: 10.1371/journal.pone.0055124. Epub 2013 Jan 30.

17.

Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.

Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M.

J Cardiol. 2010 Mar;55(2):174-9. doi: 10.1016/j.jjcc.2009.10.006. Epub 2009 Dec 1.

18.

N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C.

Alioglu E, Saygi S, Turk U, Kirilmaz B, Tuzun N, Duman C, Tengiz I, Yildiz S, Ercan E.

Cardiovasc Ther. 2013 Jun;31(3):168-73. doi: 10.1111/j.1755-5922.2011.00309.x. Epub 2011 Dec 29.

PMID:
22212518
19.

Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.

Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H.

Coron Artery Dis. 2012 Jun;23(4):265-70. doi: 10.1097/MCA.0b013e328351aacc.

PMID:
22343798
20.

Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.

Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Bellandi F.

J Am Coll Cardiol. 2008 Aug 19;52(8):599-604. doi: 10.1016/j.jacc.2008.05.026.

Supplemental Content

Support Center